Literature DB >> 29735700

Pan-cancer transcriptional signatures predictive of oncogenic mutations reveal that Fbw7 regulates cancer cell oxidative metabolism.

Ryan J Davis1,2,3, Mehmet Gönen4,5,6, Daciana H Margineantu1,2, Shlomo Handeli1,2, Jherek Swanger1,2, Pia Hoellerbauer1, Patrick J Paddison1, Haiwei Gu7,8, Daniel Raftery7,8, Jonathan E Grim2, David M Hockenbery1,2, Adam A Margolin4, Bruce E Clurman9,2.   

Abstract

The Fbw7 (F-box/WD repeat-containing protein 7) ubiquitin ligase targets multiple oncoproteins for degradation and is commonly mutated in cancers. Like other pleiotropic tumor suppressors, Fbw7's complex biology has impeded our understanding of how Fbw7 mutations promote tumorigenesis and hindered the development of targeted therapies. To address these needs, we employed a transfer learning approach to derive gene-expression signatures from The Cancer Gene Atlas datasets that predict Fbw7 mutational status across tumor types and identified the pathways enriched within these signatures. Genes involved in mitochondrial function were highly enriched in pan-cancer signatures that predict Fbw7 mutations. Studies in isogenic colorectal cancer cell lines that differed in Fbw7 mutational status confirmed that Fbw7 mutations increase mitochondrial gene expression. Surprisingly, Fbw7 mutations shifted cellular metabolism toward oxidative phosphorylation and caused context-specific metabolic vulnerabilities. Our approach revealed unexpected metabolic reprogramming and possible therapeutic targets in Fbw7-mutant cancers and provides a framework to study other complex, oncogenic mutations.

Entities:  

Keywords:  Fbw7; genomics; informatics; metabolism; ubiquitin

Mesh:

Substances:

Year:  2018        PMID: 29735700      PMCID: PMC6003503          DOI: 10.1073/pnas.1718338115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation.

Authors:  Markus Welcker; Jeffrey Singer; Keith R Loeb; Jonathan Grim; Andrew Bloecher; Mark Gurien-West; Bruce E Clurman; James M Roberts
Journal:  Mol Cell       Date:  2003-08       Impact factor: 17.970

2.  The ubiquitin ligase Fbxw7 controls adipocyte differentiation by targeting C/EBPalpha for degradation.

Authors:  Maria T Bengoechea-Alonso; Johan Ericsson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

3.  Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesis.

Authors:  Patrick A Carroll; Daniel Diolaiti; Lisa McFerrin; Haiwei Gu; Danijel Djukovic; Jianhai Du; Pei Feng Cheng; Sarah Anderson; Michelle Ulrich; James B Hurley; Daniel Raftery; Donald E Ayer; Robert N Eisenman
Journal:  Cancer Cell       Date:  2015-01-29       Impact factor: 31.743

4.  Colorectal cancer detection using targeted serum metabolic profiling.

Authors:  Jiangjiang Zhu; Danijel Djukovic; Lingli Deng; Haiwei Gu; Farhan Himmati; E Gabriela Chiorean; Daniel Raftery
Journal:  J Proteome Res       Date:  2014-08-15       Impact factor: 4.466

5.  Hyperphosphorylation regulates the activity of SREBP1 during mitosis.

Authors:  Maria T Bengoechea-Alonso; Tanel Punga; Johan Ericsson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-04       Impact factor: 11.205

6.  Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma.

Authors:  Pilar Caro; Amar U Kishan; Erik Norberg; Illana A Stanley; Bjoern Chapuy; Scott B Ficarro; Klaudia Polak; Daniel Tondera; John Gounarides; Hong Yin; Feng Zhou; Michael R Green; Linfeng Chen; Stefano Monti; Jarrod A Marto; Margaret A Shipp; Nika N Danial
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

7.  CDC4/FBXW7 and the 'just enough' model of tumourigenesis.

Authors:  Hayley Davis; Ian Tomlinson
Journal:  J Pathol       Date:  2012-04-18       Impact factor: 7.996

8.  The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability.

Authors:  Bryan King; Thomas Trimarchi; Linsey Reavie; Luyao Xu; Jasper Mullenders; Panagiotis Ntziachristos; Beatriz Aranda-Orgilles; Arianne Perez-Garcia; Junwei Shi; Christopher Vakoc; Peter Sandy; Steven S Shen; Adolfo Ferrando; Iannis Aifantis
Journal:  Cell       Date:  2013-06-20       Impact factor: 41.582

9.  Functional genomics reveal that the serine synthesis pathway is essential in breast cancer.

Authors:  Richard Possemato; Kevin M Marks; Yoav D Shaul; Michael E Pacold; Dohoon Kim; Kıvanç Birsoy; Shalini Sethumadhavan; Hin-Koon Woo; Hyun G Jang; Abhishek K Jha; Walter W Chen; Francesca G Barrett; Nicolas Stransky; Zhi-Yang Tsun; Glenn S Cowley; Jordi Barretina; Nada Y Kalaany; Peggy P Hsu; Kathleen Ottina; Albert M Chan; Bingbing Yuan; Levi A Garraway; David E Root; Mari Mino-Kenudson; Elena F Brachtel; Edward M Driggers; David M Sabatini
Journal:  Nature       Date:  2011-08-18       Impact factor: 49.962

10.  Fbw7 dimerization determines the specificity and robustness of substrate degradation.

Authors:  Markus Welcker; Elizabeth A Larimore; Jherek Swanger; Maria T Bengoechea-Alonso; Jonathan E Grim; Johan Ericsson; Ning Zheng; Bruce E Clurman
Journal:  Genes Dev       Date:  2013-12-01       Impact factor: 11.361

View more
  14 in total

1.  FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.

Authors:  Rizwan Saffie; Nan Zhou; Delphine Rolland; Özlem Önder; Venkatesha Basrur; Sydney Campbell; Kathryn E Wellen; Kojo S J Elenitoba-Johnson; Brian C Capell; Luca Busino
Journal:  Cancer Res       Date:  2020-04-29       Impact factor: 12.701

2.  Comprehensive Isotopic Targeted Mass Spectrometry: Reliable Metabolic Flux Analysis with Broad Coverage.

Authors:  Xiaojian Shi; Bowei Xi; Paniz Jasbi; Cassidy Turner; Yan Jin; Haiwei Gu
Journal:  Anal Chem       Date:  2020-08-10       Impact factor: 6.986

Review 3.  The Tumor Microenvironment in Colorectal Cancer Therapy.

Authors:  Leire Pedrosa; Francis Esposito; Timothy M Thomson; Joan Maurel
Journal:  Cancers (Basel)       Date:  2019-08-14       Impact factor: 6.639

Review 4.  Artificial intelligence in oncology.

Authors:  Hideyuki Shimizu; Keiichi I Nakayama
Journal:  Cancer Sci       Date:  2020-03-21       Impact factor: 6.716

Review 5.  Phosphorylation regulates cullin-based ubiquitination in tumorigenesis.

Authors:  Yifan Chen; Xuejing Shao; Ji Cao; Hong Zhu; Bo Yang; Qiaojun He; Meidan Ying
Journal:  Acta Pharm Sin B       Date:  2020-09-19       Impact factor: 11.413

6.  Systematic interrogation of mutation groupings reveals divergent downstream expression programs within key cancer genes.

Authors:  Michal R Grzadkowski; Hannah D Holly; Julia Somers; Emek Demir
Journal:  BMC Bioinformatics       Date:  2021-05-06       Impact factor: 3.307

Review 7.  Machine intelligence in non-invasive endocrine cancer diagnostics.

Authors:  Nicole M Thomasian; Ihab R Kamel; Harrison X Bai
Journal:  Nat Rev Endocrinol       Date:  2021-11-09       Impact factor: 43.330

Review 8.  Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine.

Authors:  Zi-Hang Chen; Li Lin; Chen-Fei Wu; Chao-Feng Li; Rui-Hua Xu; Ying Sun
Journal:  Cancer Commun (Lond)       Date:  2021-10-06

9.  Global and context-specific transcriptional consequences of oncogenic Fbw7 mutations.

Authors:  H Nayanga Thirimanne; Feinan Wu; Derek H Janssens; Jherek Swanger; Ahmed Diab; Heather M Feldman; Robert A Amezquita; Raphael Gottardo; Patrick J Paddison; Steven Henikoff; Bruce E Clurman
Journal:  Elife       Date:  2022-02-28       Impact factor: 8.713

10.  Anti-miR-135/SPOCK1 axis antagonizes the influence of metabolism on drug response in intestinal/colon tumour organoids.

Authors:  Roya Babaei-Jadidi; Hossein Kashfi; Walla Alelwani; Ashkan Karimi Bakhtiari; Shahad W Kattan; Omniah A Mansouri; Abhik Mukherjee; Dileep N Lobo; Abdolrahman S Nateri
Journal:  Oncogenesis       Date:  2022-01-19       Impact factor: 6.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.